Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?

Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?

Signal transducer and activator of transcription 3 (STAT3) controls many biological processes including differentiation, survival, proliferation, and angiogenesis. In normal healthy cells, STAT3 is tightly regulated to maintain a momentary active state. However, aberrant or constitutively activated...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology & therapeutics (Oxford) Vol. 191; pp. 74 - 91
Main Authors: Beebe, Jenny D., Liu, Jing-Yuan, Zhang, Jian-Ting
Format: Journal Article
Language:English
Published: England Elsevier Inc 01-11-2018
Subjects:
cancer therapeutics
clinical trials
drug discovery
molecular probes
small molecule compounds
STAT3 inhibitor
STAT
drug discovery
JAK
HNSCC
DBD
cancer therapeutics
molecular probes
clinical trials
SH2
STAT3 inhibitor
small molecule compounds
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Signal transducer and activator of transcription 3 (STAT3) controls many biological processes including differentiation, survival, proliferation, and angiogenesis. In normal healthy cells, STAT3 is tightly regulated to maintain a momentary active state. However, aberrant or constitutively activated STAT3 has been observed in many different cancers and constitutively activated STAT3 has been shown to associate with poor prognosis and tumor progression. For this reason, STAT3 has been studied as a possible target in the treatment of many different types of cancers. However, despite decades of research, a FDA-approved STAT3 inhibitor has yet to emerge. In this review, we will analyze past studies targeting STAT3 for drug discovery, understand possible causes of failure in these studies, and provide potential insights for future efforts to overcome these roadblocks.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0163-7258
1879-016X
DOI:10.1016/j.pharmthera.2018.06.006